Affiliation:
1. From the Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children`s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; and the Dutch Childhood Oncology Group, The Hague, The Netherlands.
Abstract
Abstract
l-asparaginase (l-Asp) is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL). The effectiveness is generally thought to result from a rapid depletion of asparagine in serum and cells. Asparagine synthetase (AS) opposes the action of l-Asp by resynthesis of asparagine. In vitro, resistance to l-Asp has been associated with up-regulation of AS mRNA expression. We monitored AS mRNA levels in leukemic cells before and during 5 days after intravenous administration of 1000 IU/m2 pegylated l-asparaginase (PEG-Asp) in a therapeutic window in children with ALL at initial diagnosis. Within 24 hours, AS mRNA levels increased by 3.5-fold and remained stable in the following 4 days. Baseline and l-Asp–induced expression levels of AS did not differ between clinically good, intermediate, and poor responders to PEG-Asp. No significant difference of AS mRNA up-regulation was found between precursor B- and T-ALL or between hyperdiploids, TEL/AML1 rearranged ALL or absence of genetic abnormalities. In 3 of 12 patients with T-ALL even a slight down-regulation of AS mRNA expression upon l-Asp exposure was found. In conclusion, although l-Asp exposure induces the expression of AS mRNA, the up-regulated gene expression does not correlate with an early clinical poor response to this drug in children with ALL.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference35 articles.
1. Capizzi RL, Bertino JR, Skeel RT. L-asparaginase: clinical, biochemical, pharmacological and immunological status. Ann Int Medicine.1971;74: 893-901.
2. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei ED, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res.1983;43: 5601-5607.
3. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochemical Pharmacology.1969;18: 2578-2580.
4. Broome JD. L-asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treatment Reports.1981;65: 111-114.
5. Andrulis IL, Argonza R, Cairney AE. Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin. Somatic Cell Mol Genet.1990;16: 59-65.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献